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Abstract
Recently revised statistics show the number of individuals living with HIV at over 33 million
worldwide, with 68% being in sub-Saharan Africa. Current HIV prevention methods, such as
condom use, monogamy and abstinence, are not always feasible. The need for improved HIV
preventative technologies remains urgent. Of these, microbicides represent a promising female-
initiated preventative method. Microbicides are designed to be applied vaginally to prevent HIV and
STI acquisition. Research is also being undertaken to assess the safety of the product during rectal
application.
The biannual Microbicides conference took place in New Delhi, India from 24–27 February 2008.
The conference was open to delegates from the scientific and medical fields, as well as communities
and advocates. In addition to microbicide research and development, the conference afforded the
opportunity for the discussion of key issues such as ethics, acceptability, access, and community
involvement.
In this conference report we provide brief summaries of recent advancements made and challenges
experienced in microbicide research and development, including updates on basic and clinical
science, social and behavioural science, and community mobilisation and advocacy activities
pertaining to clinical trials.
Background
Recent statistics by UNAIDS suggest that 2.5 million
(Range: 1.8–4.1 million) people were newly infected with
HIV in 2007. About 15.4 million (Range: 13.9–16.6 mil-
lion) women were living with HIV [1]. The disproportion-
ately higher number of infections among women requires
a commitment to address the urgent need for HIV preven-
tion tools. Microbicides are products that are currently in
development for use by women with or without their
partners' knowledge in order to reduce the growing rates
of new infections among women. The microbicide
research community spans across a multidisciplinary
team of basic and clinical scientists, social and behav-
ioural experts together with committed members of com-
munity and advocacy groups who are dedicated to finding
a women initiated HIV prevention option.
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In February 2008, the Microbicide 2008 (M2008) confer-
ence was held in the Asian Sub-continent for first time.
Held in New Delhi India, the conference attracted over
1000 delegates from the USA, Europe, Asia, Australia,
South America and Africa. This was an important meeting,
given the recent developments in the field with several
large scale efficacy trials having disappointing outcomes
[2-4].
We report on the proceedings of the Microbicides 2008
International conference, with respect to outcomes and
discussions from Track A (basic science), Track B (clinical
science), Track C (social and behavioural science) and
Track D (community and advocacy).
Track A – Basic science and preclinical development
Gustavo F. Doncel
Within Track A speakers updated a wide variety of topics
ranging from HIV entry in cervicovaginal epithelium to
delivery of microbicides by controlled-release devices. In
order to facilitate their description, the highlighted pres-
entations have been divided into four areas: sexual trans-
mission of HIV; emerging candidates; biomarkers, models
and preclinical evaluation; and formulation and delivery
systems.
Sexual transmission of HIV
In his plenary lecture, Tom Hope showed that using cervi-
cal explants, photoactivable green fluorescent protein-
labeled virus and high-resolution confocal microscopy,
HIV was seen to penetrate intact epithelium, predomi-
nantly through the interstitium. Although some virions
reached the innermost layers of the epithelium, most of
them were concentrated in the first 40 microns. This dis-
tance was enough to put the virus in contact with cellular
targets such as Langerhan's cells and intraepithelial lym-
phocytes. Similar in vivo experiments in macaques sup-
port the conclusion that HIV is able to penetrate the
genital mucosa through an apparently intact squamous
stratified epithelial layer. Derived from this conclusion is
the fact that vaginal pathologies, progestogenic hormones
or microbicides that decrease the thickness of the epithe-
lium will increase the chances of HIV to meet its target
cells. The increased number of monkeys vaginally infected
with SIV/SHIV when pre-treated with DMPA clearly sup-
ports this contention. An inflammatory reaction recruit-
ing target cells to the epithelium or the partial de-
epithelialization and disruption of epithelial permeability
caused by surfactants like nonoxynol-9 would have the
same effect.
Emerging microbicide candidates
In his contribution to the "Drug Discovery" symposium,
Martin Springer indicated that there was a significant attri-
tion of candidate compounds from discovery to phase III
clinical trials. Contrary to popular belief, most of this
attrition is due to lack of sufficient efficacy. A plenary lec-
ture by Charles Kelly provided an update of current and
emerging microbicides. The most promising microbicide
candidates in the pipeline belong to the mechanistic cate-
gories of reverse transcriptase inhibitors (RTIs), entry
inhibitors (EIs) and integrase inhibitors (INIs). Within
the RTIs, the most advanced compounds are tenofovir,
dapirivine, UC-781 and MIV-150. Among EIs, there are
CCR5 blockers (e.g., Maraviroc, RANTES analogs, M-167),
gp-120 blockers (e.g., BMS-793), fusion inhibitors (e.g., T-
1249) and a CD4 downmodulator (CADA). Two new
fully recombinant RANTES analogs (peptides) were
shown to prevent systemic viremia in 100% (5/5) of the
monkeys challenged intravaginally with 300 TCID50 SHIV
SF162P [5]. Mohammed Saifuddin reported a similar out-
come for cellulose sulfate (CS) using a low-dose multiple-
challenge X4/R5 SHIV model. Although most of the CS
treated animals showed HIV positive proviral DNA and
HIV-specific T cell responses, none of them seroconverted,
showed systemic viremia (vRNA) or produced culturable
virus.
In a symposium on "New Approaches", Robert Buckheit
outlined the significance of pyrimidinediones, a new
series of small molecules with anti-HIV activity in the sub-
nanomolar range and a dual mechanism of action inhib-
iting RT and cell entry.
Combination microbicides were cited as a logical next
step in microbicide development. Their advantages, as
discussed in a symposium on "Combination Microbi-
cides", include wider antiviral spectrum, higher genetic
barrier to resistance, higher potency, and broader cell/tis-
sue coverage. Combinations of RTIs such as tenofovir with
TMC-120 or UC-781 are being explored and developed.
Studies from different labs have shown that these combi-
nations display synergistic activity (CI ~ 0.7) and are more
potent and more active against resistant virus than their
single ingredients alone [6,7].
Speaking on the induction of resistance, John Mellors
stated that in spite of the valid concern about compounds
generating and being susceptible to resistant viruses,
product development emphasis should be put on potency
and efficacy of single-active and combination microbi-
cides. The impact of viral resistance in the context of
microbicide use is significantly lower than that of resist-
ance generated by antiviral therapy and is even smaller in
the presence of reduced number of infections due the use
of an effective microbicide.
Various delivery systems and dosage forms for combina-
tion microbicides are currently in development, as
described by Patrick Kiser, with gels and two types ofAIDS Research and Therapy 2008, 5:19 http://www.aidsrestherapy.com/content/5/1/19
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intravaginal rings being the most advanced systems. In
addition to developmental challenges, combination
microbicides also face an unexplored regulatory pathway.
Biomarkers, models and microbicide preclinical evaluation
In a panel discussion, Gustavo Doncel proposed a new
preclinical testing algorithm for the rational selection of
microbicide candidates. Three main parameters, efficacy,
safety and pharmacokinetics and pharmacodynamics
(PK/PD), are to be assessed sequentially in vitro, ex vivo
(explants) and in vivo (animals). The need to incorporate
environmental factors (e.g., pH, seminal plasma, cervi-
covaginal secretions and microflora) in these studies was
highlighted by Raina Fichorova, Ken Rosenthal, and Radi-
ana Trifonova in two symposia and one oral presentation
[8], respectively. Improvements and development of new
animal models were reported. Dorothy Patton [9] and
Cecilia Cheng-Meyer described the use of single- and mul-
tiple-dose non-human primate models of HIV vaginal
transmission to assess microbicide safety and efficacy
(roundtable discussion on "Critical gaps in microbicide
development"). Furthermore, cell-associated transmis-
sion of SIV is being optimized in a single-dose model by
Roger Le Grand and colleagues.
A new humanized mouse model based on transplantation
of human fetal bone marrow, liver and thymus into a
SCID/NOD mouse has been shown by Victor Garcia and
colleagues to be a suitable model for intravaginal HIV
infection  [10]. If validated for microbicide testing, this
model will be useful in early assessments of compound
efficacy.
Epithelial integrity, permeability and overall barrier func-
tion must be evaluated in vitro, and, if possible, in vivo,
when determining the profile of a compound in regard to
cervicovaginal safety. Betsy Herold proposed that inflam-
matory mediators, immune innate factors and antimicro-
bial activity also be critical endpoints of preclinical safety
evaluation.
Given the results of recent microbicide clinical effective-
ness trials, both Gustavo Doncel and Marla Keller cited
the importance of considering evaluating the potential of
compounds and formulations to increase or enhance sus-
ceptibility to infection. In vitro and animal models
already in existence or in development to assess this prop-
erty [11] were described during a roundtable discussion
by Marla Keller. For the most part they consist of pre-
exposing tissues or animals (e.g., mice or monkeys) to
repeated doses of microbicides before challenging them
with a suboptimal infectious dose of virus in the absence
of microbicide.
In the panel discussion on "Criteria to enable criticial
selection of microbicides", Joe Romano emphasized that
pharmacokinetic and, whenever possible, pharmacody-
namic studies, both in vitro and in vivo, are crucial to
understand how microbicides work at the tissue/cell level.
Innovative methodology is being developed to assess
these parameters, both clinically and preclinically.
The overall conclusion of the panel was that the rational
selection of microbicide candidates for further clinical
testing is a complex, iterative, evolving process that may
be improved by harmonizing/standardizing a minimum
set of assays and models, while preserving the ability of
scientists to innovate. With the addition of new, more pre-
dictive biomarkers and models of safety and efficacy, a
final Go/No Go decision should be based on a compre-
hensive preclinical package, rather than on a single "gate-
keeper" assay or model.
Microbicide formulations and delivery systems
Formulations can "make or break" a microbicide product.
For instance, in his plenary lecture Charles Lacey pointed
out that a gel containing high concentrations of glycerol
produced unacceptable adverse events in a phase I clinical
trial. The hyperosmolarity of a product has been blamed
for significant negative effects on mucosal tissue, espe-
cially that of the rectum [12]. Formulation properties can
also be used to enhance the antiviral activity of microbi-
cides [13]. Research and development of new delivery sys-
tems and dosage forms for vaginal and rectal microbicides
is ongoing. Intravaginal rings were described as especially
suitable for long-term controlled-release of hydrophobic
compounds in two different symposia by Karl Malcolm
and Patrick Kiser. Quick-dissolve thin films and tablets are
also being investigated and developed to deliver microbi-
cides, as described by Lisa Rohan and Sanjay Garg, respec-
tively, in the symposium on "Dosage Forms for
Microbicides."
Although more research is needed to determine the
acceptability of different dosage forms, it is clear that cul-
tural differences exist that may affect adherence to product
use. Since the type and characteristics of formulations and
delivery systems influence preclinical testing, clinical trial
design and, ultimately, user acceptability, formulations
and delivery systems should be designed taking all these
parameters into consideration. Furthermore, they should
be characterized and established as early as possible in the
product development process.
Track B – Clinical science
Sanjay Mehendale
Within this track there were two plenary sessions, one
with Sharon Hillier providing an update on clinical trials
of microbicide effectiveness and a second with CharlesAIDS Research and Therapy 2008, 5:19 http://www.aidsrestherapy.com/content/5/1/19
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Lacey providing an overview of how product characteris-
tics and delivery mechanisms may influence clinical trial
design. Sharon Hillier provided an overview of current
and future research products and some of the challenges
we face in the conduct of clinical trials. The new genera-
tion of ARV-containing products were introduced with
some information on planned trials.
General sessions were grouped into themes of 1) Update
on clinical trials 2) statistics, power and design of clinical
trials 3) studies in men 4) findings from early phases of
clinical trials 5) impact of other prevention trials 6) clini-
cal safety studies of vaginal microbicides and 7) lessons
learnt from cohort studies. In addition there were cross
track sessions on "when clinical trials end: challenges and
lessons learned", and "standards of care". The sessions
reported here have been divided into seven areas: Current
status and findings from phase III trials: products in the
advanced stage of evaluation; early safety trials; methodo-
logical issues in the design and implementation of clinical
trials; impact of other HIV prevention trials; clinical safety
studies; and when clinical trials end: challenges, experi-
ences and lessons learned; and a short report on cross
track sessions.
Current status and findings from phase III trials: Products in the 
advanced stage of evaluation
HPTN 035
HPTN 035 is a trial funded by the NIH to assess the effec-
tiveness of PRO 2000 and BufferGel in preventing HIV
infection in a cohort of women from South Africa,
Malawi, Zimbabwe and Zambia. A total of 3200 women
have been enrolled and are due to complete the study by
August 2008. The study is designed to have two microbi-
cide arms and two control arms (placebo and condom
only). The results are expected in early 2009 [14].
MDP 301
The microbicide development program (MDP) is a collab-
oration between scientists in the UK (Imperial college and
Clinical trials Unit of the Medical Research Council) and
scientists from Uganda, Tanzania, Zambia and South
Africa. The trial is being conducted in Africa [15]. The trial
was initially testing two concentrations of PRO 2000
(0.5% and 2%) against a placebo. However in early Feb-
ruary, the data and safety monitoring committee (DSMC)
reviewed the data to find that the 2% PRO 2000 had very
little chance of showing effectiveness. The 2% arm of the
study was subsequently dropped. The study continues to
enrol women on the 0.5% and placebo arms of the study
and is expected to complete enrolment in August 2008.
The results are expected in late 2009. Henry Luwugge
reported that gel use appeared to be high irrespective of
condom use [16]. Given the recent failures of products
with similar modes of action, it is encouraging that to date
major safety concerns have not been raised through sev-
eral interim analysis in both the above ongoing trials.
Carraguard™
A plenary presentation by Elof Johannson provided the
results of the Carraguard™ trial. Carraguard™, a sea weed
extract, was the Population Council's lead microbicide
product. A large phase III clinical trial involving 6202
women was conducted at 3 sites in South Africa; Durban,
Shoshuguwe (Pretoria) and Cape Town. The results
showed that although Carraguard™ was safe, it was not
effective in preventing HIV transmission. The results were
extremely disappointing [17].
The report of a sub study presented by Marlena Gehret to
assess the association between male circumcision and
partner sero-conversion was studied in 4579 women with
a single partner [18]. Women with partners who were cir-
cumcised were more likely to have a lower HIV incidence.
Thesla Palanee reported that incidence of STI among par-
ticipants of Carraguard™ trial showed a high prevalence of
C. trachomatis (CT) and T. vaginalis (TV) infection [19].
The prevalence rates varied across the three African sites.
At follow-up, decreasing trends in the incidence of STI was
observed. This could be due to counseling, improved
health seeking behavior and STI treatment. Risk factors
associated with HIV incidence included number of part-
ners, and being positive for CT, TV and bacterial vaginosis
(BV).
Results of another study of the impact of behavioural
change on STI incidence by Felicity Gopolang showed that
there was a reduction in the number of sex acts, number
of partners and increase in condom use [20]. However,
the observed behavioral change had no impact on the
overall STI incidence rate. Adherence to product use was
measured through the use of biomarkers, self-report and a
combination of both methods. Nearly 96% of the 6005
women self-reported adherence to the product. Gel used
during vaginal sex was 57%, condom use 64%, both gel
and condom use 62%; women reported having sex 2.5
times per week and applicator insertion 0.9 times per
week. Analysis of self-reported condom use and micros-
copy for sperms in vaginal swabs (wet mount and TV In
pouch) showed detectable spermatozoa among that
reporting condom use in 62.5%. This study indicated that
information given by women on condom use may not be
reliable.
CAPRISA 004
In addition to trials of current generation of microbicides,
an update was provided on the first proof of concept ARV-
based microbicide trial being conducted in South Africa.
CAPRISA 004 is a two arm study comparing a coitally
dependent dose of 1% tenofovir against a placebo. Enroll-AIDS Research and Therapy 2008, 5:19 http://www.aidsrestherapy.com/content/5/1/19
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ment is scheduled to be completed by July and results
expected in 2010 [21].
Savvy
The vaginal microbicide Savvy was evaluated in a Phase III
Nigerian trial which required the use of pre-loaded single
use gel applicators and a placebo, and enrolled 2142
women. The trial was terminated early at 75% completion
level. High pregnancy rates were observed across both
study arms. There was no evidence of the effectiveness of
the product in preventing HIV infection. Paul Feldblum
concluded that more conservative HIV incidence estima-
tions should be employed and more effective family plan-
ning measures should be advocated among the trial
participants [22].
Early safety trials
HPTN 059
Sharon Hillier presented some very encouraging results of
the safety and coitally dependent use of 1% tenofovir over
six months [23]. The HPTN 059 trial also tested the safety
and acceptability of 1% Tenofovir gel and was conducted
in India and two US sites [24]. Soma Das reported 96%
retention over 6 months and 80–85% product adherence.
Preliminary results indicate that the safety profile of the
product was excellent and toxicity end points were com-
parable in product and placebo arms. There were no sig-
nificant sexually transmitted infection (STI) acquisitions.
Daily gel use was close to 20% and over 75% with sex.
Some tenofovir was detectable in blood in 75% of those
who had used gel in the past 24 hours. Strategies such as
locator forms, participant tracking database, telephonic
contacts, home visits, clinic diary and follow-up schedule
chart were used to facilitate retention. Male involvement
and proper scheduling helped in achieving remarkably
high retention rate in this study.
In a study presented by Jill Schwartz, two 1% tenofovir gel
dosing regimens are currently being evaluated in pharma-
cokinetic studies on samples collected by cytobrush and
biopsies from the posterior fornix. Advanced assays are
being used for local and systemic compartment evalua-
tions.
Dapivirine vaginal gel (Gel-002)
Gel-002 with active ingredient Dapivirine recently under-
went safety and tolerability testing in studies in Rwanda,
South Africa and Tanzania. This NNRTI was tested in a gel
form to assess its safety and acceptability. Shanique
Smythe presented the data from this 3 dose study requir-
ing 42 days' product use. The product was shown to be
safe and well-tolerated, possibly warranting further inves-
tigation of the gel [25]. Annalene Nel presented the results
of a South African phase I pharmacokinetic study of Gel-
002 among 18 women in 3 groups. Low systemic levels of
the product were detected up to 24 hours after exposure
[26].
Cellulose acetate phthalate (CAP 13% gel)
Charles Lacey presented a Phase I study of this hyper-
osmolar vaginal gel in 10 women which was stopped fol-
lowing unacceptable adverse events. A continuous, heavy
and watery discharge was noted in half of the women par-
ticipating in the study [27].
Vivagel
Vivagel (SPL7013 Gel), a product with anti-HIV and anti-
herpes properties, was initially tested in macaque models
and subsequently in two studies in men and women.
Clare Price and Maureen Momanyi reported findings from
Vivagel studies. Safety after penile application of 2 mg of
product for 7 days showed no genital irritation, genital
pruritus, penile dryness or scrotal tingling and the results
were similar in circumcised and uncircumcised men. The
product was found to be safe and well tolerated. The
acceptability was good and there was no evidence of sys-
temic absorption [28,29].
Special cross track sessions: Key-note addresses, symposia and panel 
discussions
Within track B three symposia were organized on "Rectal
Microbicides", "Moving Microbicides into susceptible
populations" (discussed under track D) and "Microbi-
cides and HIV positive women" (discussed under track D)
and two key-note addresses on "Methodological issues in
design and implementation of clinical trials". Addition-
ally, two panel discussions were conducted on the
"Impact of other HIV prevention trials" and "Clinical
safety studies". The major observations during these ses-
sions are summarized below.
Studies on rectal exposures of microbicides
An ex-vivo challenge study of the safety of the rectal
microbicide UC-781 on explants has been completed and
the data is still blinded. A subsequent interim report of the
safety study at 50% completion was presented by Peter
Anton [30]. Interim data from 36 rectally-exposed men
and women at UCLA, USA indicated that the product was
safe and well-tolerated. Product adherence was good and
no Grade III or IV adverse reactions were observed. Even
at 75% study completion results remain unchanged. The
study employed a vaginal applicator for rectal use. Further
research needs to be conducted on the design and accept-
ability of the vaginal applicator for rectal use. Mucosal
immunity studies following two weekly applications for 6
weeks indicated no changes in the mucosal and cytokine
profiles of the three groups over time.AIDS Research and Therapy 2008, 5:19 http://www.aidsrestherapy.com/content/5/1/19
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Methodological issues in the design and implementation of 
clinical trials
Doug Taylor gave a very informative talk on statistical
power. He expressed the challenges we face in assessing
trial outcomes on factors that impact on power. There are
several factors that contribute to the power of the study to
show efficacy. These include high retention rates, adher-
ence to product use, women taken off the product due to
pregnancy and high incidence rates. He expressed the
importance of conducting effectiveness trials over efficacy
trials. To overcome the challenges of high incidence of
pregnancy and its impact on power, new generation of
products will be tested for safety during pregnancy.
Zeda Rosenberg discussed the challenges in doing phase
III studies with enough power when a product is believed
to be effective in preventing HIV transmission. She
explained that the current trials do not measure efficacy,
but it is inferred that a woman has become infected after
unknown number of sex acts. She stressed that effective-
ness trials are more important because they measure both
efficacy as well as adherence. It is being increasingly felt
that alternative study designs should be employed for the
fast tracking of microbicide development and testing. The
best among the next generation products must be selected
for safety evaluation and should be evaluated early for
futility after employing measures to improve adherence.
They should be powered for licensure. Alternate studies of
superior design will allow for improved ways of measur-
ing adherence and reductions of risk taking behaviour,
and at the same time test the effectiveness of the product
in HIV prevention.
Impact of other HIV prevention trials
Globally the agenda of HIV prevention research includes
behavioral change, circumcision, diaphragm use, pre-
exposure prophylaxis and STI control. We have learned
that adherence significantly impacts the outcomes of tri-
als. Trials have also had setbacks due to unexpected fewer
number of study end-points resulting from low HIV inci-
dence. According to Lut van Damme and colleagues,
lower than expected HIV incidence rates highlight the
importance of site preparatory studies and newer technol-
ogies to estimate HIV incidence.
HSV-2 suppressive therapy for HIV prevention
The HPTN 039 study, conducted by Connie Celum,
explored whether HSV-2 suppression by Acyclovir could
reduce the risk of HIV acquisition [31]. Although the pre-
cise reasons why this trial failed to show the desired result
in Africa are unknown, the lack of adherence to Acyclovir
prophylaxis may appear to be one of the reasons. This is
the second trial of Acyclovir which failed to show effec-
tiveness in preventing HIV. A trial conducted in Tanzania
showed similar results [32].
Male circumcision
Cate Hankins presented the outcome of the three trials on
male circumcision in the prevention of HIV. The results
showed the male circumcision provided up to 60% pro-
tection against female to male transmission of HIV. The
current challenges were to roll out male circumcision as
an HIV prevention option in developing countries.
Vaginal diaphragm for the prevention of HIV
MIRA (Methods of Improving reproductive Health in
Africa) was a trial conducted to assess the effectiveness of
the vaginal diaphragm in the prevention of HIV. The trial
was completed in early 2007 and the results reported in
July of the same year [2]. The study was conducted at 3
sites in Southern Africa; Zimbabwe and South Africa
(Johannesburg and Durban). The study showed that the
vaginal diaphragm did not provide any added benefit
when used in addition to the current prevention package
of male condoms, risk reduction counseling and treat-
ment for STI. Kelly Blanchard presented an overview of
the trial and the results [33].
Clinical safety studies
Clinical safety studies evaluate integrity of epithelium,
effects on the penis, vaginal microflora, pregnancy and
impact on body function due to systemic absorption or
inflammatory response. Symptoms and colposcopy do
not necessarily indicate safety and recent outcomes of tri-
als suggest that there is a need to identify markers for gen-
eral toxicity at an early stage of clinical trials. It is essential
to establish safety both in HIV negative and positive
women. The possibility of extension of the product in
endocervix and uterus warrants some method like Mag-
netic Resonance Imaging (MRI) for its safety evaluation,
which might increase the cost of a trial substantially.
Jonathan Weber emphasized the urgent need for long-
term safety assessment and strategies to avoid products
going into large scale trials and then showing increased
safety concerns.
Cross track sessions
Standard of Care
In a cross track session on standard of care, Kathy Shapiro
presented the results of a mapping exercise by the Global
Campaign for Microbicides. Key conclusions from this
study were that clinical trial sites are providing better qual-
ity (access, affordability, skills of providers) of services.
Also there are a range of standards of care being offered at
sites depending on public sector services in the area. She
outlined recommendations that came out of the exercise
and subsequent meetings; urging that communities
should be engaged in decisions about how to manage trial
standard of care; future trials should consider co-locating
with existing local care facilities and use the opportunity
to improve the services provided, improve the quality ofAIDS Research and Therapy 2008, 5:19 http://www.aidsrestherapy.com/content/5/1/19
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care and build the capacity of health care providers; trial
sites should also improve their referral systems and facili-
tate women's access to care at referral facilities; and as
much as possible to also establish formal agreements with
referral sites to avoid the unnecessary repetition of tests
and other procedures.
When clinical trials end: Challenges, experiences and lessons learned
Three speakers in this session, Lut Van Damme, Gita Ram-
jee and Manju Chatani provided their perspectives on the
impact of the unexpected closure of clinical trials mainly
due to safety concerns. Lut Van Damme provided an over-
view of the challenges faced by sponsors during the clo-
sure of Cellulose Sulphate trial in early 2007. Key lessons
learned were the need for communication, and visiting
trial sites immediately. She stressed that one is never pre-
pared emotionally and practically for sudden closure of
trials.
Manju Chatani's contribution to a panel discussion out-
lined a number of lessons learned from the advocates' per-
spective after the closure and premature end of
microbicide trials. These include; the need to strengthen
communication strategies in the microbicides field, the
need to select effective community speakers and inform
them routinely on developments and be informed from
them as well and the need to conduct ongoing media
training for these spokesperson. A key lesson is to work
closely with media agencies on an ongoing basis – so that
media is well-versed with protocols of microbicides
research and is an effective partner. There is a value in sce-
nario planning in anticipation of different possible
results. These experiences have led to advocates having
increased access to researchers and information, and as a
result there is more coordination and collaboration
among these stakeholders.
The MMCI completed a case study of lessons learned dur-
ing the unexpected closures of the Cellulose Sulfate trial
and the inflammatory press coverage that followed in
South Africa. The case study analyzes the handling of the
crisis in light of conflicting pressures at the international,
local, and trial site level. It highlights the particular chal-
lenges of ensuring that relevant stakeholders and trial par-
ticipants are informed of the findings before they are
released to the media.
Gita Ramjee gave her perspective as an investigator at trial
sites. Many of the sites employ skilled staff to conduct
clinical trials. When trials end either prematurely or due to
natural completion, it is difficult to sustain trial staff if no
other products are available to go into large scale trials.
This poses a huge challenge for trial sites. Unexpected clo-
sures have been challenging due to sensationalist articles
in the media that impact on HIV prevention efforts. Effec-
tive communication and scenario planning of trial out-
comes need to be in place well in advance of the trial
outcomes. She stressed the involvement of the commu-
nity in the dissemination of results and preparation of
results in local language. All speakers stressed the impor-
tance of communication and collaboration with various
disciplines prior to release of the results.
In addition to the cross track sessions there were special
symposia on microbicides and HIV positive women. The
symposium presenters were Wafaa EL Sader and Anna
Forbes. Both presenters stressed the importance of involv-
ing HIV positive women in HIV prevention efforts. The
second symposium was on moving microbicide research
to vulnerable populations. Richard Beigi presented on the
need for involving pregnant women in clinical trials to
assess the safety of products. Ian McGowan stressed the
importance of involving men who have sex with men and
development of rectal microbicides. Kathy Slack high-
lighted the growing incidence of HIV in adolescents and
the need to involve adolescents in clinical trials of micro-
bicides and other prevention technologies.
Track C – Behavioural and social science
Elizabeth E. Tolley
The social science Track C program featured a wide range
of research topics and methodological approaches. Seven
abstract-driven sessions and three invited presentations
addressed issues pertaining to adherence; behavioural and
social science methods and tools; acceptability; commu-
nity involvement; partner roles; vulnerable populations;
and future access.
Cultural influence
In his plenary talk, Ravi Varma described the ways that
culture influences men's and women's risk through gen-
der roles and relationships – and will ultimately deter-
mine whether, with whom and how gels may be used.
Some men's first sexual encounters were with other men;
many men who engage in sex with other men are married.
Men's perception of risk from such behaviours was low –
especially if one was the "penetrator". Men who engaged
in extramarital sex (whether with other women or men)
were six times more likely to report wife abuse than those
who did not. Yet, gender norms perpetuate women's sub-
mission to coercive sex in marriage and prevent frank dis-
cussions about sexuality and risk. Varma concluded that
while the introduction of microbicides may act as a cata-
lyst, more encompassing gender transformative strategies
were needed to reduce men's and women's risk of HIV in
India. Indeed, the association between microbicide intro-
duction and gender norm transformation arose in South
Africa as well, where Fern Terris-Prestholt found a prefer-
ence for promotion of microbicides as a means to
empower women and/or prevent HIV – rather than aAIDS Research and Therapy 2008, 5:19 http://www.aidsrestherapy.com/content/5/1/19
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method to enhance sexual pleasure, in a survey of 1017
women in three townships in Johannesburg, South Africa
[34].
Several studies reminded us that the cultural context of
microbicide use may vary across countries and for differ-
ent groups within a population. This included access to
partially effective microbicides and its impact on vulnera-
bility of sex workers [35], types of products, frequency and
timing of use [36] and modelling studies to ascertain
impact of microbicide introduction [37].
Communities
Communities are not homogenous. Multiple stakehold-
ers, including civil society groups [38], healthcare provid-
ers [39], clinical trial staff [40] and trial participants
influence trial acceptability through their understanding
and expectations of clinical trials. One important factor
influencing successful trial implementation is community
perception of the quality and types of HIV-related treat-
ment, care and support to be provided to those who
screen out of the trial or sero-convert, their families or the
broader community. Community involvement and part-
nership is critical to initiation and completion of trials to
ensure such concerns are adequately addressed. The bene-
fit of such involvement was evident in premature closure
of the Cellulose Sulphate trial [41], where intensive coun-
selling, community education and on-going informed
consent processes led to relatively positive community
reactions despite a spate of negative and inaccurate pub-
licity about closure. While there are cultural differences,
trial sites have to develop novel strategies to explain the
understanding of trial methodologies such as randomiza-
tion and placebo [42,40]. This requires ongoing improve-
ment of the informed consent process and understanding.
In addition it was pointed out that communities should
have a sense of ownership for successful community
involvement. New trials will implement comprehensive
socio-behavioural and community preparedness activities
to allow for community partnerships [38,43].
Trials and clinic settings
The clinical trial setting itself is likely to influence individ-
uals' risk behaviours; several studies examined changes in
trial participants' behaviours post randomization. Among
2140 women randomized to the diaphragm arm of the
MIRA trial, just over 22% reported using diaphragms
instead of condoms at all visits, and over 60% reported
doing so at some visits [2,33]. Women who consistently
reported substituting the diaphragm for condoms (versus
never report this behaviour) were more likely to be
engaged in sex work, report domestic violence or sex with
a drunken partner, believe that diaphragms protect
against HIV/STIs, and are less likely to know that con-
doms can be used with diaphragms.
While Ariane Van der Straten's study identified the poten-
tial for therapeutic misconception and condom migra-
tion, Adelaide Mzimela's and Elizabeth Tolley's studies
found that trial participation may, in fact, lead to higher
use of condoms [44,45].
Partners
Women's ability to negotiate trial participation with inti-
mate partners may determine who enrolls in trials and
how well they are able to adhere to gel and other trial
requirements. Anna Dladla-Qwabe examined the rela-
tionship between consistent gel adherence and disclosure
to partners of study participation/gel use in a study of 263
women in Hlabisa, South Africa participating in the
HPTN 035 trial [46]. She noted that women reporting
consistent gel use were more likely to have disclosed both
their study participation and their use of gel to partners
than women who reported inconsistent use. Local behav-
ioural investigators at several MDP trial sites examined the
role of men in gel use. Disclosure to gel use was reported
by many participants in several trials and, in general, men
supported women's use of the product. Lubrication pro-
vided by the gel increased sexual pleasure hence the prod-
ucts were acceptable [47-51].
On the other hand Petina Musara examined covert use of
microbicides in a sub-study of HPTN 035 in Zimbabwe
[52]. Women reported a motivation to use microbicides
clandestinely when they suspected a partner to be unfaith-
ful; when he was unwilling to use condoms; or when he
was HIV positive. However, requirements for timing and
insertion of gel, as well as difficulties of storage limited
covert use. Community leaders also expressed negative
opinions about covert use, further constraining this
approach.
Participants
Several Track C presentations identified individual-level
factors as influencing acceptability and use of microbi-
cides. These included perceptions of product attributes,
perception of risk and efficacy to communicate with a
partner about risk and/or negotiate risk reduction behav-
iours. For example, in PRO 2000/5 study of 3157 women,
Jessica Dhookie noted very few reports of difficulty with
insertion (> 1%) – all reported in week 4 follow-up only
[50]. Alex Carballo-Diéguez examined the acceptability of
rectal microbicide vehicle-related attributes in a cross-over
trial of 77 HIV-negative cohort of men having sex with
men [53]. Men and their partners were significantly more
likely to prefer gel over suppositories, reporting that gel
was associated with greater sexual satisfaction and
resulted in less leakage, bloating or other side effects than
did suppositories. In a cross-sectional U.S.-based study
called the Phoenix Project, Kate Morrow found that a per-
son's attitudes and characterizations of risk were influ-AIDS Research and Therapy 2008, 5:19 http://www.aidsrestherapy.com/content/5/1/19
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enced by specific partner contexts and that willingness to
use a microbicide was affected by both those individual
and relationship elements [54]. In India, Elizabeth Tolley
found somewhat similar measures of risk perception and
partner context, as well as product attitudes and percep-
tion of protection efficacy, to predict consistency of con-
dom use among clinical trial participants, but only
product attitudes to predict gel use [45].
While several presentations focused on the individual,
couple-related or other factors that might explain partici-
pants' level of adherence in trials, only one presentation
focused on approaches to optimizing participants' adher-
ence within trials. Approaches include motivational inter-
viewing to assist individual participants in identifying and
pre-empting situations that could lead to non-adherence
of gel [55].
Inside the body
Finally, in her keynote address, Kate Morrow described
her collaboration with basic scientists. As they work to
optimize microbicide gel deployment, her aim is to ade-
quately measure individual perceptions' of deployment
(or other product properties) and link them to biophysi-
cal characteristics – so that such characteristics can be
assessed by the user. Such a linkage would enable product
developers to more rationally select formulations that
have a greater chance of success – because participants
may be more adherent.
Cross-cutting themes
An important cross-cutting theme for the Microbicide
2008 Track C program was the need for social scientists to
pay more attention to measurement. Topics pertaining to
measurement included 1) the development and use of
psychometric scales; 2) triangulation of information
through mixed method approaches; and 3) assessment of
different data collection strategies. In her keynote address,
Geraldine Barrett described her work to develop a more
valid and reliable measure of unplanned pregnancy for
use in the United Kingdom. Barrett relied on a two step
process, first using qualitative methods to identify and
define key factors associated with women's attitudes
towards a recent pregnancy; and then the use of quantita-
tive methods to develop a six item psychometric scale that
more accurately captures the range of positions women
might have towards pregnancy. Kate Morrow used a simi-
lar process of qualitative research and psychometric scale
development to behavioural tools that better assess
women's perception of how microbicide products per-
form within the body.
In addition to improving measures for specific concepts
through psychometric scale development, Robert Pool
provided examples of how the use of multiple data collec-
tion methods could improve understanding and ulti-
mately the accuracy of data on adherence [56]. Ana
Ventuneac described the advantages and shortcomings of
three data collection strategies: 1) interactive voice
response systems; 2) web-based and computer assisted
self-interviews; and 3) use of hand-held devices [57]. Such
approaches can increase privacy and frequency of data
collection, thereby decreasing social desirability and recall
biases that lead to inaccurate reporting.
A second cross-cutting theme was the challenge of imple-
menting behavioural and social science research in micro-
bicide trials and the need for greater collaboration and
networking within these disciplines [58].
Track D – Policy, advocacy and community
Kim Dickson
Track D highlighted the issues of policy, advocacy and
community relating to microbicides research, develop-
ment, access and introduction. The Track D presentations
and discussions revolved around the key themes of com-
munity involvement; managing stakeholders expecta-
tions; modelling the impact of microbicides introduction;
engaging a broader audience in microbicides advocacy;
and other key issues.
Community involvement
A keynote talk by Mangala Patil on defining the commu-
nity and the importance of partnerships for HIV research
emphasized how the community advisory board (CAB)
has an important role to play to be the bridge between
trial participants, the broader community in the region,
and researchers, scientists and clinicians. Another key role
of the CAB was to communicate effectively to dispel mis-
conceptions or myths that participants or the trial com-
munity might have.
The presentations on community involvement high-
lighted how community engagement has become more
sophisticated with more innovative strategies being
employed. These strategies included the use toll free lines,
homes visits and peer educators. They outlined how civil
society engagement helps microbicide trials in many
ways, including: helping research to avoid pitfalls, main-
taining accountability between researchers and commu-
nity, mobilizing new public resources, facilitating open
and fair communication between different stakeholders
thereby increasing accountability and increasing trust in
the communities. The presentations reinforced the impor-
tance of assessing the needs of the community and involv-
ing them in all stages of research.
Although advocates continue to request for early commu-
nity engagement in the protocol development process,
including the concept development stage many research-AIDS Research and Therapy 2008, 5:19 http://www.aidsrestherapy.com/content/5/1/19
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ers feel this is difficult. Morenike Ukpong presented new
strategies to involve community at all levels [59].
A presentation by Majorie Nakimuli [60] outlined the
effectiveness of peer leaders in Uganda from the Makere/
Mulago/CONRAD Center project in the mobilization,
recruitment and retention of participants. These peer lead-
ers worked alongside the CAB and belonged to the com-
munity where trial participants were from. They were
crucial in mobilizing the community through training
and leadership [61].
Anna Forbes explained the process the Global Campaign
for Microbicides spearheaded to identify seven key gaps in
civil society involvement throughout the microbicide
research and development and post-development process
and make recommendations for seven key priority actions
for how funders, researchers, governments, and civil soci-
ety working together could address each of these gaps
[62]. The Microbicide Development Strategy (MDS) also
proposes a funding mechanism to donor agencies to pro-
vide a window to key civil society organizations working
on microbicides research, advocacy and development.
Managing stakeholder expectations of trial results
Presentations in these sessions emphasized the impor-
tance of preparing for communications and unexpected
results and the need to understand how to frame data to
meet the needs of different audiences including advocates,
policy makers, providers, participants and communities.
A presentation from the Microbicides Media Initiative
(MMCI) by Deborah Baron emphasized that developing
clear, concise and consistent messages on interpreting trial
results has become a top priority for the microbicides field
whether studies are halted prematurely or finish on sched-
ule [63]. The Microbicides Media and Communication
Initiative (MMCI) was launched in 2005 to help the wider
microbicide field anticipate and respond proactively to
the communications challenges posed by large-scale trials
in Africa and Asia. Since then, the MMCI has become a
forum for communications staff, researchers and advo-
cates to share expertise, resources and ideas across institu-
tions and networks.
Modelling the impact of microbicides introduction
Charlotte Watts used mathematical modelling to explore
the relationship between 'efficacy' and 'effectiveness'
measures [64]. Phase III microbicide trials provide the
strongest evidence about HIV impact. For coitally depend-
ent products, inevitably the measure of trial effectiveness
will be lower than the per sex act protection provided,
with greater differences for lower consistency use. Esti-
mates of contraceptive efficacy come from prospective
observational studies comparing users with non-users.
Non-user dependent methods are > 96% effective, with
rates less than 80% being viewed as inadequate. Estimates
of condom HIV efficacy come from comparisons of infec-
tion rates among discordant couples with different
reported levels of condom use, with meta analysis suggest-
ing that consistent use reduces cumulative risk by 87%,
and inconsistent use by 60%. The 90% – 95% condom
efficacy term refers to per sex act reduction in risk, and is
derived from modelling. Impact of microbicides is differ-
ent on: risk per sex act, on individual risk if used overtime,
on HIV incidence in a controlled trial setting and on pop-
ulation HIV incidence following widespread provision.
The presentation concluded that the findings highlight
the need for clarity in the way in which the terms 'efficacy'
and 'effectiveness' are used across fields, and for care when
communicating and interpreting trial results and that we
need to find better ways of communicating the results to
different stakeholders.
An keynote presentation by Sally Blower on modelling the
use of rectal microbicides in 'bathouses' concluded that
moderately effective rectal microbicides (50% efficacy)
with moderate use (30% use) could have substantial
impact on HIV prevention in these bathouses. Blower
highlighted the impact of anti retroviral based (ARV)
based microbicides derived from modelling studies. She
concluded that microbicides are important empowerment
tools for women but paradoxically ARV based-microbi-
cides could benefit men more than women in terms of
infection prevented and infections prevented per resistant
cases, especially if the microbicide was 'high-risk' (in
terms of the possibility for acquiring resistance).
Engaging a broader audience in microbicides advocacy
Presentations in these sessions focused on the issues of
rectal microbicides advocacy reaching young women and
addressing the issues of HIV positive women.
Rectal microbicides
A comprehensive advocacy approach, spanning science,
policy and the community, is needed to bring safe, accept-
able and effective rectal microbicides to market. James
Pickett of the International Rectal Microbicides Working
Group expressed that data consistently reveal that men
and women around the world engage in receptive anal
intercourse, often without the use of a condom [65]. He
stressed that the development of a rectal microbicide,
which could provide some protection from HIV transmis-
sion during anal intercourse, is hampered by biological
and scientific challenges, socio-cultural and political bar-
riers such as stigma, denial and homophobia, and a lack
of adequate resources necessary for the development of a
robust pipeline of rectal microbicide candidates. He called
for rectal safety studies on all viable vaginal microbicides
and stressed that testing of additional commercial lubri-AIDS Research and Therapy 2008, 5:19 http://www.aidsrestherapy.com/content/5/1/19
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cants for rectal safety be encouraged and regulatory bodies
and policies should be supportive too. Nesha Haniff pre-
sented her experiences of rectal microbicides advocacy
through the work of Jamaica Aids Support for Life [66].
Moving microbicides into susceptible populations
Adolescents
The topic of adolescents was covered in both track B and
D. Martha Brady highlighted the gap in policy and pro-
grammes to build the social and health platform for the
adolescents (10–19 years), youth (15–24 years), espe-
cially young girls [67]. Conventional "youth programs"
and "adolescent sexual reproductive health" programs do
not reach the majority of vulnerable adolescent girls, who
remain overlooked and underserved. Any effort to reach
adolescents girls and young women with a microbicide
product would need to address the heterogeneity of this
potential user group: they have diverse needs and situa-
tions they deal with. Targeted messages and a range of
protection strategies and services for a diverse group of
girls will be needed.
Microbicides and HIV positive women
Sean Philpott, Louise Binder [68] and a roundtable panel
of HIV positive women, researchers and advocates
stressed the need to involve HIV positive women in micro-
bicides research. They mentioned that as microbicides are
being developed, HIV-positive women are raising numer-
ous issues related to safety, trial design and ethics, which
require consideration and implementation in current tri-
als and future research. The roundtable discussions out-
lined how research with HIV positive women and
engagement of HIV positive women in advocacy has
increased. The discussions emphasized that communica-
tion channels to keep HIV positive women's groups
apprised of new developments on microbicides research
should be developed.
Other key issues
Helen Rees's insightful key note on lessons from experi-
ence with other reproductive health technologies stressed
that introduction of new products and widespread access
and use take a long time; it took more than 30 years for
the tampon to gain widespread acceptability and use. Les-
sons drawn from the introduction of the Lippes Loop and
Norplant have taught us to carefully evaluate service capa-
bility, the technology and consumer acceptability before
introducing new technologies. Rees summarised key les-
sons from product introduction as; price; political con-
text; distribution channel; marketing and targeting of
advertising.
Panel sessions were held to discuss issues key issues
including; 'Confronting the evidence' and planning for
introduction and access. The 'evidence' discussion con-
cluded that the level 'evidence' needed differs depending
on the 'perceived' acceptability of the intervention, the
researcher and complexity of implementation. Partici-
pants and communities need to be consulted about what
evidence is acceptable and informed of new findings. The
'access and introduction' session revealed that; sponsors
and trialists are working together and thinking about
access after Phase III trials and are including cost, distribu-
tion and manufacturing in contracts to access their prod-
ucts for trials.
Satellite sessions and workshops
In addition to the full scientific programme, there were
several satellite sessions. The NIH held a grantsmanship
workshop for young investigators which included ses-
sions on the components of a successful grant application,
electronic submission tips, funding opportunities for
international investigators and opportunities for collabo-
ration.
There was a workshop for junior social scientists organ-
ized by the Office for AIDS Research (OAR) which covered
a wide range of pertinent topics related to social science
research within a clinical trial setting.
A pre-conference workshop on 'Health Advocacy" was co-
hosted by AMAG, GCM, INN, NCHI and PWN. The work-
shop aimed to provide a status report on microbicide sci-
ence and advocacy including the history of the field, a
snapshot of the current status of the field, and discussion
on some of the issues that participants were likely to raise.
The Alliance of Microbicide Development had a work-
shop on industrializing microbicides which covered a
wide range of topics such as toxicology guidelines, manu-
facturing chemical and biological microbicides, intellec-
tual property considerations and regulatory issues.
A symposium on rectal microbicides was co-hosted by
AMFAR, UCLA AIDS Institute and the University of Pitts-
burgh. The objective was to provide an overview of recent
advances in rectal microbicide development, improve-
ment in applicator design and an update on advocacy
directed towards increasing funding for rectal microbicide
research.
Finally, there was a workshop on ARV and ARV resistance
hosted by NIH/OAR. Given the importance of the topic
with recent advances in microbicide and PreP (Pre-expo-
sure Prophylaxis) trials, this workshop covered an over-
view of the microbicide pipeline, description of ARV
resistance and the impact of potential resistance on partic-
ipants, and some of the key challenges in ARV-based
microbicide clinical trials.AIDS Research and Therapy 2008, 5:19 http://www.aidsrestherapy.com/content/5/1/19
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Summary
The Microbicides 2008 Conference in New Delhi was a
resounding success. Despite the recent set backs in the
HIV prevention field, with many products showing lack of
effectiveness in preventing HIV, the scientists at the con-
ference showed progress in the field of basic science. Val-
uable lessons learned from previous trials across all
disciplines from basic and social sciences, as well as com-
munity involvement and advocacy, have greatly improved
our understanding of the complexity of conducting HIV
prevention research in a resource poor setting. Scientists
reaffirmed their commitment to a continued search for a
women-initiated HIV prevention option. The next meet-
ing, planned for 2010, will be held in Pittsburgh, USA.
The conference will be chaired by Sharon Hillier, Ian
McGowan, and Gita Ramjee.
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